Keʻena Honua

Ma Iune 11, ua hoʻolaha ʻo Kelun-Biotech ua hāʻawi ʻia ka Breakthrough Therapy Designation (BTD) i kāna TROP2 ADC drug sac-TMT (佳泰莱) i hoʻomohala kūʻokoʻa ʻia, i hui pū ʻia me ka PD-L1 monoclonal antibody tagitanlimab (科泰莱) e ke Center for Drug Evaluation (CDE) o ka National Med...E heluhelu hou aku»

Ma ka lā 29 o Mei, ua ʻāpono ka National Medical Products Administration (NMPA) i ke kūʻai aku ʻana o Zanidatamab, i waiho ʻia e BeiGene, no ka mālama ʻana i nā poʻe maʻi me ka maʻi kanesa biliary tract (BTC) i hiki ʻole ke hoʻopau ʻia ma kahi kūloko a i ʻole metastatic i loaʻa mua i ka lāʻau lapaʻau systemic a hōʻike i ke kiʻekiʻe HER2...E heluhelu hou aku»

Ma Iune 04, 2025, ua hoʻolaha ʻo Akeso ua ʻāpono ka National Medical Products Administration (NMPA) i ka antibody bispecific PD-1/CTLA-4 mua loa o ka hui, cadonilimab, no ka lāʻau lapaʻau mua o ka maʻi ʻaʻai cervical mau loa, recurrent, a metastatic paha, i hui pū ʻia me ka platinum...E heluhelu hou aku»

Ma ka lā 29 o Mei, ua ʻāpono ka National Medical Products Administration (NMPA) i ka HER2-targeted antibody-drug conjugate (ADC) trastuzumab rezetecan (SHR-A1811) no ke kūʻai aku ʻana. Ua hōʻike ʻia ia he monotherapy no ka mālama ʻana i nā maʻi makua me ka unresectable locally advanced a metastatic non-small ...E heluhelu hou aku»

Ma ka lā 21 o Mei, 2025, ua hoʻolaha ʻo InnoCare Pharma ua ʻae ʻia ka ʻĀina Hoʻokele Huahana Lapaʻau Lahui o Kina (NMPA) no Minjuvi® (tafasitamab), kahi antibody monoclonal i hoʻololi ʻia e Fc-modified cytolytic CD19 e kuhikuhi ana i ka humanized, i hui pū ʻia me lenalidomide, a ukali ʻia e ka Minjuvi monotherapy, no ka t...E heluhelu hou aku»

Ma ka lā 22 o Mei, 2025, ua hoʻolaha ʻo Allist Pharmaceuticals ua ʻae ʻia kāna lāʻau lapaʻau hou ʻo Airuikai (Glecirasib Citrate Tablets), he mea hoʻopaʻa KRAS-G12C, no ka hoʻomaka ʻana i ka mākeke e ka National Medical Products Administration (NMPA). ʻAe ka ʻae ʻia iā Airuikai e hoʻohana ʻia no ka mālama ʻana...E heluhelu hou aku»

Ma ka lā 22 o Mei, 2025, ua hoʻolaha ʻo Kelun Bio ua ʻae ʻia ka noi no kahi hōʻailona hou o kāna trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, i ʻike ʻia hoʻi ʻo SKB264/MK - 2870) (®) e ke Kikowaena no ka Loiloi Lāʻau Lapaʻau (...E heluhelu hou aku»

I ke Kaua Lōʻihi e Kūʻē i ke Kanesa, Ke Puka Mau Nei Nā Mea Kaua Hou e Kūʻē i ke Kanesa, e Lawe Mai Ana i ka Manaʻolana Hou i nā Maʻi I ke kaua lōʻihi ma waena o ke kanaka a me ke kanesa, ke puka mai nei nā mea kaua hou e kūʻē i ke kanesa kekahi ma hope o kekahi, e lawe mai ana i ka manaʻolana hou i nā maʻi. Ma ke ʻano he mea hou e ʻālohilohi ana...E heluhelu hou aku»

I ka makahiki 2021, ua hana kahi maʻi kanesa pancreatic 67 makahiki i kahi hana mana lapaʻau. Ma hope o ka ʻoki ʻana, nā manawa he nui o ka chemotherapy, a me ka hāʻule ʻana o ka lāʻau TIL, ʻo ka hoʻāʻo lapaʻau o ka lāʻau TCR-T cell āna i komo ai ua hoʻemi i ka metastases o ka māmā ma 72% i loko o 6 mahina...E heluhelu hou aku»

Ma ka lā 12 o Mei, 2025, hoʻolaha ʻo CARsgen i ka ʻikepili lapaʻau mua no CT0596, kahi CAR-T i hoʻolālā ʻia e BCMA allogeneic i hoʻomohala ʻia me ka hoʻohana ʻana i ka paepae THANK-u Plus™. Ke loiloi ʻia nei ʻo CT0596 i loko o kahi noiʻi lapaʻau mua no ka myeloma multiple relapsed/refractory (R/R MM) a i ʻole relapsed/refractor...E heluhelu hou aku»

Ma ka lā 9 o Mei, 2025, ua hoʻolaha ʻo Hansoh Pharmaceutical ua ʻae ʻia kahi hōʻailona hou no Ameile (nā papa almonertinib mesylate) no ke kūʻai aku ʻana. ʻO ka hōʻailona hou no ka mālama adjuvant o nā poʻe maʻi makua me ka maʻi ʻaʻai māmā ʻaʻole liʻiliʻi (NSCLC) nona nā puʻupuʻu i loaʻa ka epidermal growth factor re...E heluhelu hou aku»

Ma ka lā 1 o Mei, 2025, ua hoʻolaha ʻo Hansoh Pharmaceutical ua loaʻa i ka hui ponoʻī ʻo B7-H4-targeted antibody-drug conjugate (ADC) HS-20089 no ka injection i ka ʻae ʻia e hoʻokomo ʻia ma ke ʻano he Breakthrough-Therapy-Designated Drug e ka National Medical Products Administration (NMPA) o Kina, me...E heluhelu hou aku»